Search company, investor...

Total Raised

$301.59M

Investors Count

4

Deal Terms

1

Funding, Valuation & Revenue

10 Fundings

ImmunityBio has raised $301.59M over 10 rounds.

ImmunityBio's latest funding round was a PIPE - II for $10M on December 29, 2023.

ImmunityBio's valuation in December 2018 was $4,000M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/29/2023

PIPE - II

$10M

$99M

0

FY undefined

2

12/12/2022

PIPE

$50M

$99M

0

FY undefined

1

12/21/2020

Reverse Merger

$99M

0

FY undefined

6

3/14/2019

Unattributed - VI

$99M

$99M

0

FY undefined

10

12/27/2018

Corporate Minority - II

$99M

$4,000M

0

FY undefined

10

Date

12/29/2023

12/12/2022

12/21/2020

3/14/2019

12/27/2018

Round

PIPE - II

PIPE

Reverse Merger

Unattributed - VI

Corporate Minority - II

Amount

$10M

$50M

$99M

$99M

Investors

Valuation

$99M

$99M

$99M

$99M

$4,000M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

1

6

10

10

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

ImmunityBio Deal Terms

1 Deal Term

ImmunityBio's deal structure is available for 1 funding round, including their Corporate Minority - II from December 27, 2018.

Round

Corporate Minority - II

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Corporate Minority - II

$99M

$99M

$99M

$99M

$99M

$99M

ImmunityBio Investors

4 Investors

ImmunityBio has 4 investors. Oberland Capital invested in ImmunityBio's PIPE - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

12/29/2023

12/29/2023

1
PIPE - II

Debt & Specialty Finance

New York

00/00/0000

00/00/0000

NantCapital

Subscribe to see more

Corporate Venture

California

00/00/0000

00/00/0000

NantKwest

Subscribe to see more

Corporation

California

00/00/0000

00/00/0000

Celgene

Subscribe to see more

Corporation

New Jersey

First funding

12/29/2023

00/00/0000

00/00/0000

00/00/0000

Last Funding

12/29/2023

00/00/0000

00/00/0000

00/00/0000

Investor

NantCapital

NantKwest

Celgene

Rounds

1
PIPE - II

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Debt & Specialty Finance

Corporate Venture

Corporation

Corporation

Location

New York

California

California

New Jersey

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare ImmunityBio to Competitors

Prokarium Logo
Prokarium

Prokarium is a biopharmaceutical company that focuses on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company was founded in 2012 and is based in London, U.K.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.